AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor as first-line ...

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data ...

As genetic and biomarker tests become more common, so do new therapies that target specific tumor types and may lead to better outcomes ...

Angle announced on Friday the successful completion of assay development projects for AstraZeneca and Eisai, further ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the disease getting worse in a study, a positive outcome in the development of ...

Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN ... III trial to use a circulating tumor DNA-guided approach to detect the emergence ...

(RTTNews) - AstraZeneca plc (AZN ... registrational Phase III trial employing a circulating tumor DNA (ctDNA)-guided methodology to identify the emergence of endocrine resistance and to facilitate ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

AstraZeneca has advanced its push to make camizestrant ... Physicians monitored circulating tumour DNA to spot ESR1 mutations. If a mutation was found before disease progression, patients switched ...